hypercholesterolemia

PDUFA test 3
Flag link:
Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Sanofi and Regeneron Announce Presentation of Detailed Positive Results from Four Pivotal Alirocumab Trials at ESC Congress 2014
Yahoo/PR Newswire
Sanofi
Regeneron
alirocumab
hypercholesterolemia
Flag link:
Harvard Study Questioning Cholesterol Drugs in Low-Risk Cases Survives Oxford Challenge
Harvard Study Questioning Cholesterol Drugs in Low-Risk Cases Survives Oxford Challenge
BusinessWeek
hypercholesterolemia
statins
Flag link:
New Detailed Phase 3 Data Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With A Rare And Serious Genetic Disorder That Causes High Cholesterol
New Detailed Phase 3 Data Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With A Rare And Serious Genetic Disorder That Causes High Cholesterol
Yahoo/PR NewsWire
cholesterol
hypercholesterolemia
evolocumab
Amgen
Flag link:
FDA Sprinkles Some Rain On the PCSK9 Inhibitor Parade
FDA Sprinkles Some Rain On the PCSK9 Inhibitor Parade
Forbes
PCSK9 inhibitors
Regeneron
Sanofi
hypercholesterolemia
Flag link:
Amgen Goes 6 for 6 Fighting Cholesterol
Amgen Goes 6 for 6 Fighting Cholesterol
Motley Fool
Amgen
cholesterol
hypercholesterolemia
evolocumab
Flag link:
Amgen Inc’s Next Blockbuster Drug Delivers
Amgen Inc’s Next Blockbuster Drug Delivers
Motley Fool
Amgen
AMG 145
hypercholesterolemia
cholesterol
Flag link:
The Next Cholesterol-Fighting Blockbuster Drug?
The Next Cholesterol-Fighting Blockbuster Drug?
Motley Fool
cholesterol
hypercholesterolemia
Regeneron
Sanofi
alirocumab
Flag link:
EMA rejects Genzyme re-examination request for Kynamro
EMA rejects Genzyme re-examination request for Kynamro
Yahoo/Fly on the Wall
Europe
Genzyme
Kynamro
Sanofi
hypercholesterolemia
Flag link:
New drug holds promise as therapy for rare and deadly cholesterol disorder
New drug holds promise as therapy for rare and deadly cholesterol disorder
Equities.com
lomitapide
hypercholesterolemia
Aegerion
Flag link:
Isis Trading Halts as FDA Reviews Key Drug's Risks
Isis Trading Halts as FDA Reviews Key Drug's Risks
PharmPro
Isis Pharmaceuticals
Kynamro
hypercholesterolemia
Flag link:
Aegerion CEO on Cholesterol Drug Lomitapide
Aegerion CEO on Cholesterol Drug Lomitapide
Bloomberg
Aegerion
lomitapide
hypercholesterolemia
Flag link:
Kowa Pharma, Eli Lilly PREVAIL US study of Livalo met primary endpoint of LDL-C reduction
Kowa Pharma, Eli Lilly PREVAIL US study of Livalo met primary endpoint of LDL-C reduction
Pharmabiz
Eli Lilly
Livalo
hypercholesterolemia
LDL cholesterol
Flag link:
Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results
Aegerion Pharmaceuticals Announces Lomitapide 78-Week Phase III Clinical Data Consistent With Earlier Results
Yahoo/Globe NewsWire
Aegerion
lomitapide
hypercholesterolemia
Flag link:
Next big drug against cholesterol takes shape
Next big drug against cholesterol takes shape
HealthNews
Regeneron
Sanofi
hypercholesterolemia
PCSK9
Amgen
Merck
Alnylam
Bristol-Myers Squibb
REGN727
Flag link:
Genzyme and Isis submit European MAA for mipomersen
Genzyme and Isis submit European MAA for mipomersen
Pharmabiz
Genzyme
Isis Pharmaceuticals
mipomersen
hypercholesterolemia
Flag link:
Valeant's subsidiary Biovail acquires Canadian rights to Cholestagel from Genzyme
Valeant's subsidiary Biovail acquires Canadian rights to Cholestagel from Genzyme
pharmabiz
Biovail
Genzyme
Cholestagel
hypercholesterolemia
colesevelam
Flag link: